{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:36:22Z","timestamp":1794472582734,"version":"4.9.1"},"reference-count":15,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2026,2,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy (DAPT) reduces recurrent stroke in patients with minor non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack (TIA). However, real-world prescribing remains heterogeneous. The Shanghai Stroke Service System (4S) initiated a guideline-focused education and audit-feedback programme aimed at improving standard DAPT use for minor strokes since 2019. This study evaluates its impact on the adherence to DAPT and clinical outcomes before and after this initiative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study used data from the 4S registry. Consecutive adult patients with acute minor ischaemic stroke (National Institutes of Health Stroke Scale\u22643) or high-risk TIA (ABCD\n                      <jats:sub>2<\/jats:sub>\n                      score \u22654) between 2015 and 2021 were enrolled. Patients with suspected cardioembolism or who received intravenous thrombolysis were excluded. Standard DAPT was defined as aspirin plus clopidogrel initiated within 24 hours. Education throughout the 4S on the use of DAPT was carried out during 2018\u20132019. Outcomes during postimplementation period (2019\u20132021) were compared with preimplementation period (2015\u20132018). The primary outcome was standard DAPT rate; secondary outcomes included in-hospital stroke recurrence and non-standard DAPT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 58\u2009491 patients, standard DAPT increased by 13.6% (95%\u2009CI 12.8 to 14.4; p&lt;0.001) following 4S initiative. In-hospital stroke recurrence rate decreased by about 1% (aOR=0.91, 95%\u2009CI 0.85 to 0.98; p=0.01), driven primarily by improvements in tertiary hospitals. Paradoxically, non-standard DAPT also increased by 10.0% (95% CI 9.3 to 10.7; p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Following implementation of a regional guideline-education initiative within 4S, standard DAPT use increased and overall in-hospital stroke recurrence declined. However, the parallel rise in non-standard DAPT use observed in secondary hospitals highlights persistent practice variability and the need for targeted quality-improvement strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02735226\">NCT02735226<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2025-004815","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:35:19Z","timestamp":1770906919000},"page":"svn-2025-004815","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of a regional guideline-education initiative on dual antiplatelet therapy use in minor non-cardioembolic stroke: a pre\u2013post analysis from the Shanghai Stroke Service System"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct02735226","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5620-6226","authenticated-orcid":false,"given":"Sha","family":"Han","sequence":"first","affiliation":[{"name":"Department of Neurology, Huashan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-5592","authenticated-orcid":false,"given":"Jiawen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Hu","sequence":"additional","affiliation":[{"name":"Institute of Medical Research, Huashan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6630-112X","authenticated-orcid":false,"given":"Yi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-0130","authenticated-orcid":false,"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026021206351268000_svn-2025-004815v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"2026021206351268000_svn-2025-004815v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410"},{"key":"2026021206351268000_svn-2025-004815v1.3","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375"},{"key":"2026021206351268000_svn-2025-004815v1.4","doi-asserted-by":"publisher","DOI":"10.1177\/23969873221100032"},{"key":"2026021206351268000_svn-2025-004815v1.5","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1161\/STROKEAHA.119.026044","article-title":"Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke: A Nationwide, Multicenter Registry-Based Study","volume":"50","author":"Kim","year":"2019","journal-title":"Stroke"},{"key":"2026021206351268000_svn-2025-004815v1.6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.006474","article-title":"Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15\u2009000 Patients From a Nationwide, Multicenter Registry","volume":"13","author":"Lee","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026021206351268000_svn-2025-004815v1.7","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70012","article-title":"Dual antiplatelet therapy after minor strokes or high-risk TIA: Evidence from the Austrian stroke registry","volume":"32","author":"Krebs","year":"2025","journal-title":"Eur J Neurol"},{"key":"2026021206351268000_svn-2025-004815v1.8","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.123.043769"},{"key":"2026021206351268000_svn-2025-004815v1.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24157","article-title":"Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke","volume":"5","author":"Xian","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026021206351268000_svn-2025-004815v1.10","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1269292","article-title":"Appropriate use of antiplatelet medications following transient ischemic attacks and stroke: a 9-year study from the Middle East","volume":"14","author":"Naveed","year":"2023","journal-title":"Front Neurol"},{"key":"2026021206351268000_svn-2025-004815v1.11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033611","article-title":"Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT\/CHANCE Trial Treatment","volume":"13","author":"Kim","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026021206351268000_svn-2025-004815v1.12","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.122.041660"},{"key":"2026021206351268000_svn-2025-004815v1.13","doi-asserted-by":"publisher","DOI":"10.1177\/1747493018765492"},{"key":"2026021206351268000_svn-2025-004815v1.14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/17474930221125993","article-title":"Effect of the Shanghai Stroke Service System (4S) on the quality of stroke care and outcomes: A prospective quality improvement project","volume":"18","author":"Xu","year":"2023","journal-title":"Int J Stroke"},{"key":"2026021206351268000_svn-2025-004815v1.15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1212\/WNL.0b013e3181b59a6e","article-title":"Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program","volume":"73","author":"Smith","year":"2009","journal-title":"Neurology (ECronicon)"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2025-004815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:35:20Z","timestamp":1770906920000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2025-004815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":15,"alternative-id":["10.1136\/svn-2025-004815"],"URL":"https:\/\/doi.org\/10.1136\/svn-2025-004815","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}